ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Tenpoint Therapeutics has launched with $70 million in series A investments to develop therapies that reverse vision loss. The company will pursue both ex vivo approaches, in which cells are manipulated outside the eye and then administered, and in vivo reprogramming, which acts on cells in place within the eye. “If we think of the eye . . . as a camera, it’s easier to access certain parts of the camera depending on what part you need to exchange,” says Tenpoint CEO Eddy Anglade. The firm says it aims to replace cell types in both inherited and age-related conditions.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X